Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

JCL Bioassay Corp Amends Consolidated Mid-year and Full-year Outlook for FY Ending March 31, 2013; Cancels Year-end Dividend Payment Plan for FY Ending March 31, 2013


Wednesday, 7 Nov 2012 01:30am EST 

JCL Bioassay Corp announced that it has raised its consolidated mid-year outlook for revenue from JPY 1,010 million to JPY 1,029 million, but lowered its consolidated mid-year outlook for operating profit (loss) from JPY 5 million to JPY (28 million), ordinary profit (loss) from JPY (19 million) to JPY (104 million), net profit (loss) from JPY (14 million) to JPY (261 million) and earning per share (loss) from JPY (4.24) to JPY (78.96) for the fiscal year ending March 31, 2013. The Company also lowered its consolidated full-year outlook for revenue from JPY 2,552 million to JPY 2,391 million, operating profit from JPY 118 million to JPY 94 million, ordinary profit (loss) from JPY 70 million to JPY (18 million), net profit (loss) from JPY (62 million) to JPY (200 million) and earning per share (loss) from JPY (18.76) to JPY (60.50) for the same fiscal year. This is due to the recording of impairment loss, loss on valuation of investment securities and reversal of allowance for doubtful accounts. The Company also resolved to cancel its year-end dividend of JPY 3.00 per share, for the same fiscal year. 

Company Quote

398.0
-7.0 -1.73%
24 Oct 2014